Beneath both signals runs a single deeper current: the regulatory system is not blocking psychedelic medicine out of hostility or ignorance — it is generating exactly the friction that a genuinely novel class of neurologically active, cardioactively complex compounds requires. What is forming beneath the surface is a scientific and procedural infrastructure that did not exist five years ago. The 76% probability that FDA will issue formal SSRI-psychedelic interaction guidance within eighteen months is not a pessimistic signal — it is the system working. Similarly, the 78% probability of a formal clinical hold or safety guidance on at least one ibogaine IND before end of 2026 reflects not obstruction but the agency doing precisely what the evidence demands. The highest trajectory available from here is one in which the friction itself becomes foundation: mandatory cardiac monitoring REMS for ibogaine programs, standardized washout protocols across all psychedelic NDAs, and a regulatory vocabulary that finally matches the pharmacological reality of these compounds. That infrastructure, once built, is what makes durable approval possible. The question is not whether it will be built — it will — but how many programs are delayed, restructured, or temporarily paused while it is.
The human cost of that pause is not abstract. There are veterans — tens of thousands of them — for whom ibogaine represents not a clinical option but a last option, who have watched the Stanford data emerge with something close to desperate hope, who understand cardiac monitoring protocols not as bureaucratic obstruction but as the price of being taken seriously. There are people living inside treatment-resistant depression who are enrolled in psilocybin trials, who have already tapered off SSRIs — a physically and emotionally grueling process — and who are now sitting inside a question about whether the washout timing was even correct. What becomes genuinely possible for these people, on the highest available trajectory, is not speed but solidity: a regulatory framework rigorous enough that the medicines they need can reach them not as emergency exceptions but as standard of care, covered, monitored, and reproducible. That is worth the friction. That does not make the waiting easy.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The medicine is older than the fear. The healing is older than the wound.
87%
Psilocybin rescheduling won't get a Congressional vote by January 2027
Congress (specifically the House or Senate) won't vote on a psilocybin rescheduling bill before January 3, 2027, when the current Congress ends. No bill has made it out of committee, and party leaders aren't pushing it as a priority. A small bipartisan group of members supports it, but they don't have the votes or the political machinery to force a floor vote.
→ A psilocybin rescheduling vote won't happen in Congress before January 2027 because the bill is stuck in committee and leaders won't bring it to the floor.
Resolves: 2027-01-03 · USA
LEGISLATION
the precise call ▾
Federal psilocybin scheduling reform will not receive a floor vote in the 119th Congress (ending January 3, 2027).. No psilocybin rescheduling bill has been reported out of committee. Leadership prioritization is elsewhere. A bipartisan coalition exists but is numerically insufficient and organizationally fragmented. No triggering event — FDA approval, major CBO scoring, or leadership deal — is visible on the hor
85%
No psychedelic rescheduling at federal level before 2028
The federal government won't move psilocybin, MDMA, LSD, or DMT from Schedule I (the strictest category) to a lower schedule before 2028. This matters because rescheduling is the only legal path that lets doctors prescribe these drugs widely — and it requires the FDA to first approve one as a medicine, which hasn't happened yet.
→ No classical psychedelic will be rescheduled federally before 2028 because none has FDA approval yet, and that approval is a legal requirement Congress can't bypass.
Resolves: 2028-01-01 · USA
LEGISLATION
the precise call ▾
No federal rescheduling of any classical psychedelic — psilocybin, MDMA, LSD, DMT — will occur before 2028.. No classical psychedelic has an FDA-approved NDA, which is the statutory prerequisite for DEA rescheduling that would survive legal challenge. Congressional standalone rescheduling bills lack floor votes and leadership support in the 119th Congress. The pathway does not exist within the timeframe.
78%
Ibogaine heart safety will block FDA progress through mid-2027
The cardiac (heart) safety problem with ibogaine — specifically QT prolongation — will be the main reason the FDA doesn't approve ibogaine or clear new trials for at least 18 more months. No new research has emerged to prove the heart risk is safe or manageable, so the safety concern stays locked in place as the blocking point. Ibogaine advocates are pushing, but the FDA won't move until the heart problem is resolved.
→ Ibogaine won't move forward with the FDA until someone proves the heart rhythm problem is manageable — and that proof doesn't exist yet.
Resolves: 2027-07-01 · USA
REGULATORY
the precise call ▾
Ibogaine cardiac safety will remain the primary regulatory gating factor for all FDA and Congressional ibogaine progress through at least mid-2027.. QT prolongation data is now sufficient to anchor FDA safety reviews and Congressional risk calculus. No counterbalancing safety data resolving the cardiac signal is expected within 12 months. Veteran advocacy pressure exists but is insufficient to override a documented safety signal at the FDA level
72%
FDA will warn about ibogaine heart rhythm dangers by end of 2026
The FDA will formally halt or restrict at least one ibogaine drug trial (called a clinical hold) or issue safety guidance because of a cardiac problem called QT prolongation — a heartbeat irregularity that can cause sudden death. Ibogaine is known to affect the heart's electrical system, and researchers have already documented this risk in peer-reviewed studies. The FDA uses this evidence to trigger safety holds.
→ The FDA will formally halt or warn about ibogaine trials because the drug causes dangerous heart rhythm changes that FDA reviewers can't ignore.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
FDA will issue a formal clinical hold or safety guidance on at least one ibogaine IND citing QT prolongation before end of 2026.. A growing body of peer-reviewed cardiac complication data — specifically QT prolongation — constitutes the evidentiary record FDA reviewers require to justify a clinical hold. QT prolongation is a documented regulatory tripwire across therapeutic classes. Active ibogaine INDs face this risk asymmetr
70%
FDA won't publish SSRI-psychedelic interaction guidance by November 2027
The FDA won't issue official written instructions for doctors on how long patients taking SSRI antidepressants need to wait before using psychedelic medicines. Animal studies hint at an interaction risk, but the FDA needs human trial data to write guidance — and that data doesn't exist. FDA guidance documents take 12–24 months to write and approve internally, plus they need public comment periods. Official guidance won't land before November 2027.
→ The FDA won't publish official guidance on how to safely mix SSRIs and psychedelics until at least November 2027 because it needs human data and time to write the rules.
Resolves: 2027-11-07 · USA
REGULATORY
the precise call ▾
FDA will not publish a formal guidance document on SSRI-psychedelic washout protocols before November 2027.. Mouse fluoxetine interaction data is mechanistically suggestive but does not constitute the human trial data FDA requires before issuing binding guidance. Guidance documents require internal review cycles of 12–24 months minimum, public comment periods, and cross-division coordination. The 18-month